Clinical Trial Update: An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing nivolumab alone, nivolumab plus ipilimumab, or nivolumab plus platinum-doublet chemotherapy versus platinum doublet chemotherapy in stag…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Opdivo (nivolumab) (nivolumab)
• Platinum-based chemotherapy (platinum doublet)
• Yervoy (Ipilimumab) (Ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2025-10-30